Galmed Pharmaceuticals (GLMD) Q1 2025 Earnings
GLMD·Reported May 22, 2025·Before market open
Galmed Pharmaceuticals reported Q1 2025 revenue of $1.5M. Diluted EPS came in at $-0.62 (+77.5% YoY), beat the $-0.89 consensus by $0.27.
Revenue
$1.5Mmet estimate
Consensus: $1.5MDiluted EPS
$-0.62beat by $0.27
Consensus: $-0.89
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2025 Earnings FAQ
Common questions about Galmed Pharmaceuticals's Q1 2025 earnings report.
Galmed Pharmaceuticals (GLMD) reported Q1 2025 earnings on May 22, 2025 before market open.
Galmed Pharmaceuticals reported revenue of $1.5M and diluted EPS of $-0.62 for Q1 2025.
Revenue beat the consensus estimate of $1.5M by -. EPS beat the consensus estimate of $-0.89 by $0.27.
Compared to the same quarter a year prior, diluted EPS grew 77.5% from $-2.76.